-
ALSO READ
Alkem Laboratories announces closure of USFDA inspection of Baddi facility Morepen Gets US FDA clearance for its Bulk Drug Montelukast Sodium Sun Pharma gets 3 observations from USFDA for Halol plant Alembic Pharma gets 3 observations from USFDA for Gujarat plant Alkem gets EIR report from USFDA for Baddi facility -
Following USFDA inspection and receipt of one Form 483 observation
Alkem Laboratories announced that the USFDA had conducted an inspection at the Company's manufacturing facility located at St. Louis, USA from 12 March, 2018 to 16 March, 2018. In response to the one Form 483 observation issued by the US FDA, the Company has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
RECOMMENDED FOR YOU